Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 45
Summary
- Conditions
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Small Lymphocytic Lymphoma
- Waldenstrom Macroglobulinemia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
OUTLINE: Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 d...
OUTLINE: Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 3 months for 3 years.
Tracking Information
- NCT #
- NCT02339922
- Collaborators
- National Cancer Institute (NCI)
- Millennium Pharmaceuticals, Inc.
- Investigators
- Principal Investigator: Ajay K. Gopal Fred Hutch/University of Washington Cancer Consortium
Get Well Soon